vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and Sunlands Technology Group (STG). Click either name above to swap in a different company.

OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $10.1M, roughly 1.3× Sunlands Technology Group). Sunlands Technology Group runs the higher net margin — 24.0% vs -488.0%, a 511.9% gap on every dollar of revenue. Over the past eight quarters, Sunlands Technology Group's revenue compounded faster (0.6% CAGR vs -5.3%).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

STG Partners, LLC (STG) is an American private equity firm and based in Menlo Park, California. Its predecessor, Symphony Technology Group ("Symphony") was founded in 2002 by Romesh Wadhwani, William Chisholm, and Bryan Taylor. In 2017, Symphony was reorganized as STG Partners. As of March 2025, STG Partners managed approximately $12 billion in 19 pooled investment vehicle for its clients. The firm itself has less than one billion dollars in assets.

OCUL vs STG — Head-to-Head

Bigger by revenue
OCUL
OCUL
1.3× larger
OCUL
$13.3M
$10.1M
STG
Higher net margin
STG
STG
511.9% more per $
STG
24.0%
-488.0%
OCUL
Faster 2-yr revenue CAGR
STG
STG
Annualised
STG
0.6%
-5.3%
OCUL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
OCUL
OCUL
STG
STG
Revenue
$13.3M
$10.1M
Net Profit
$-64.7M
$2.4M
Gross Margin
88.0%
88.5%
Operating Margin
-526.5%
26.5%
Net Margin
-488.0%
24.0%
Revenue YoY
-22.4%
Net Profit YoY
-33.6%
EPS (diluted)
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
STG
STG
Q4 25
$13.3M
Q3 25
$14.5M
$10.1M
Q2 25
$13.5M
$9.3M
Q1 25
$10.7M
Q4 24
$17.1M
$9.7M
Q3 24
$15.4M
Q2 24
$16.4M
$10.0M
Q1 24
$14.8M
Net Profit
OCUL
OCUL
STG
STG
Q4 25
$-64.7M
Q3 25
$-69.4M
$2.4M
Q2 25
$-67.8M
$1.4M
Q1 25
$-64.1M
Q4 24
$-48.4M
$1.8M
Q3 24
$-36.5M
Q2 24
$-43.8M
$2.2M
Q1 24
$-64.8M
Gross Margin
OCUL
OCUL
STG
STG
Q4 25
88.0%
Q3 25
87.8%
88.5%
Q2 25
85.6%
85.2%
Q1 25
88.2%
Q4 24
92.8%
83.3%
Q3 24
89.9%
Q2 24
90.8%
85.2%
Q1 24
91.0%
Operating Margin
OCUL
OCUL
STG
STG
Q4 25
-526.5%
Q3 25
-472.3%
26.5%
Q2 25
-502.6%
15.2%
Q1 25
-597.5%
Q4 24
-296.1%
13.4%
Q3 24
-298.2%
Q2 24
-265.1%
Q1 24
-214.0%
Net Margin
OCUL
OCUL
STG
STG
Q4 25
-488.0%
Q3 25
-477.3%
24.0%
Q2 25
-503.9%
15.4%
Q1 25
-598.7%
Q4 24
-283.3%
18.2%
Q3 24
-236.6%
Q2 24
-266.3%
21.5%
Q1 24
-438.9%
EPS (diluted)
OCUL
OCUL
STG
STG
Q4 25
$-0.27
Q3 25
$-0.38
Q2 25
$-0.39
Q1 25
$-0.38
Q4 24
$-0.25
Q3 24
$-0.22
Q2 24
$-0.26
$0.31
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
STG
STG
Cash + ST InvestmentsLiquidity on hand
$737.1M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$654.3M
$17.7M
Total Assets
$808.1M
$41.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
STG
STG
Q4 25
$737.1M
Q3 25
$344.8M
$15.1M
Q2 25
$391.1M
Q1 25
$349.7M
Q4 24
$392.1M
$15.6M
Q3 24
$427.2M
Q2 24
$459.7M
$18.7M
Q1 24
$482.9M
Total Debt
OCUL
OCUL
STG
STG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.5M
Q3 24
Q2 24
$1.8M
Q1 24
Stockholders' Equity
OCUL
OCUL
STG
STG
Q4 25
$654.3M
Q3 25
$258.2M
$17.7M
Q2 25
$305.9M
$12.6M
Q1 25
$265.9M
Q4 24
$315.3M
$10.7M
Q3 24
$352.0M
Q2 24
$377.7M
$7.6M
Q1 24
$408.0M
Total Assets
OCUL
OCUL
STG
STG
Q4 25
$808.1M
Q3 25
$410.9M
$41.2M
Q2 25
$451.3M
$40.3M
Q1 25
$405.9M
Q4 24
$457.9M
$42.4M
Q3 24
$490.4M
Q2 24
$517.1M
$41.3M
Q1 24
$538.9M
Debt / Equity
OCUL
OCUL
STG
STG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.14×
Q3 24
Q2 24
0.24×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
STG
STG
Operating Cash FlowLast quarter
$-54.2M
Free Cash FlowOCF − Capex
$-57.1M
FCF MarginFCF / Revenue
-430.9%
Capex IntensityCapex / Revenue
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
STG
STG
Q4 25
$-54.2M
Q3 25
$-50.7M
Q2 25
$-55.2M
Q1 25
$-44.7M
Q4 24
$-39.4M
Q3 24
$-36.6M
Q2 24
$-24.8M
Q1 24
$-33.9M
Free Cash Flow
OCUL
OCUL
STG
STG
Q4 25
$-57.1M
Q3 25
$-56.7M
Q2 25
$-56.5M
Q1 25
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
Q2 24
$-25.5M
Q1 24
$-34.1M
FCF Margin
OCUL
OCUL
STG
STG
Q4 25
-430.9%
Q3 25
-390.0%
Q2 25
-419.7%
Q1 25
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
-155.4%
Q1 24
-231.1%
Capex Intensity
OCUL
OCUL
STG
STG
Q4 25
21.4%
Q3 25
41.2%
Q2 25
9.3%
Q1 25
18.1%
Q4 24
1.2%
Q3 24
0.6%
Q2 24
4.5%
Q1 24
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons